Notably, Pembrolizumab, Nivolumab, and Cemiplimab are representative anti-PD-1 agents,104 while Atezolizumab, Avelumab, and Durvalumab are examples of anti-PD-L1 agents.105 The use of these drugs has been associated with improved outcomes in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), and other cancers. This evidence concerns the gene CD274 and renal cell carcinoma.